Prothena Receives $50 Million Milestone Payment from Novo for ATTR-CM Progress

Rare Daily Staff

Prothena said it received a $50 million milestone payment from Novo Nordisk after reaching a patient enrollment goal in a late-stage clinical trial of a potential new treatment for a rare heart disease.

The payment is tied to the ongoing phase 3 CLEOPATTRA study testing the company’s experimental therapy coramitug, formerly known as PRX004, for transthyretin (ATTR) amyloidosis with cardiomyopathy — a condition in which misfolded proteins build up in the heart, leading to heart failure.

Coramitug, an antibody drug designed to clear amyloid deposits, is being evaluated in about 1,280 participants worldwide. Novo Nordisk expects the study to finish in 2029, according to the company’s announcement.

Prothena has now earned $150 million in total milestone payments under its 2021 agreement with Novo Nordisk, which acquired Prothena’s ATTR amyloidosis program and related intellectual property for up to $1.2 billion in potential payments tied to clinical and commercial goals.